- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06630702
Aplicación de SCS epidural torácica para el tratamiento de FOG en pacientes con enfermedad de Parkinson avanzada
Aplicación de la estimulación de la médula espinal epidural torácica (SCS) para controlar la congelación de la marcha (FOG) en pacientes con enfermedad de Parkinson avanzada
Spinal cord stimulation (SCS) has proven to be effective for pain that is unresponsive to medication. This technique involves an anesthesiologist or a neurosurgeon placing stimulation electrodes at the thoracic vertebrae to provide pain relief. Although SCS is not currently a standard treatment for patients with Parkinson's disease, recent studies have shown that Parkinson's patients who experience intolerable pain and undergo SCS treatment not only experience pain relief but also show improvements in gait and other Parkinson's symptoms. Therefore, the investigators aim to use temporary, minimally invasive SCS electrodes to help patients with nrFOG (non-responsive Freezing of Gait) improve their stability and reduce their risk of falls.
Descripción general del estudio
Estado
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Kai-Hsiang Chen, M.D.
- Número de teléfono: 522610 +886-3-5326151
- Correo electrónico: stanleychen1230@gmail.com
Ubicaciones de estudio
-
-
Hsinchu City
-
Hsinchu, Hsinchu City, Taiwán, 300
- Reclutamiento
- National Taiwan University Hospital Hsin-Chu Branch
-
Contacto:
- Kai-Hsiang Chen, M.D.
- Número de teléfono: 522610 +886-3-5326151
- Correo electrónico: stanleychen1230@gmail.com
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Age:40-85 years old.
- Patients with primary Parkinson's disease who have been diagnosed by a movement disorder specialist for more than 5 years. Although they have a clear response to drugs, they have a frozen gait that cannot be controlled by drugs. Lower limb pain may be present with or without Parkinson's non-motor symptoms.
- No other secondary gait problems.
Exclusion Criteria:
- Atypical Parkinson's disease.
- Patients with spinal cord injuries.
- Medication-controlled frozen gait.
- It is expected that there are lesions near the implantation area causing spinal canal stenosis or myelopathy (can be ruled out by MRI).
- It is expected that the implantation area has undergone previous surgery or there is infection near the implantation area, which may affect the success rate of implantation or increase concerns about complications (such as severe extraspinal adhesion, or spinal cord damage in previous surgeries).
- People with abnormal coagulation function (such as hemophilia patients) or those who have been controlled by long-term use of antithrombotic drugs and cannot stop taking them in a short period of time.
- CDR (Clinical Dementia Rating Scale) ≧2. 8. Those who are allergic to developer.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Implantación de SCS
|
300Hz/300us 130Hz/300us 60Hz/300us |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Gait parameters --- foot rotation [degtree]
Periodo de tiempo: Day 0, Day 2, Day 3, Day 4, and Day 7
|
(1)Measured by plantar pressure distribution measurement systems (100 Hz, FDM-T, Zebris Medical GmbH, Germany) with a maximum gait track of 6 meters. |
Day 0, Day 2, Day 3, Day 4, and Day 7
|
|
Gait parameters --- step length [cm]
Periodo de tiempo: Day 0, Day 2, Day 3, Day 4, and Day 7
|
(1)Measured by plantar pressure distribution measurement systems (100 Hz, FDM-T, Zebris Medical GmbH, Germany) with a maximum gait track of 6 meters. |
Day 0, Day 2, Day 3, Day 4, and Day 7
|
|
Gait parameters --- stride length [cm]
Periodo de tiempo: Day 0, Day 2, Day 3, Day 4, and Day 7
|
(1)Measured by plantar pressure distribution measurement systems (100 Hz, FDM-T, Zebris Medical GmbH, Germany) with a maximum gait track of 6 meters. |
Day 0, Day 2, Day 3, Day 4, and Day 7
|
|
Gait parameters --- step width [cm]
Periodo de tiempo: Day 0, Day 2, Day 3, Day 4, and Day 7
|
(1)Measured by plantar pressure distribution measurement systems (100 Hz, FDM-T, Zebris Medical GmbH, Germany) with a maximum gait track of 6 meters. |
Day 0, Day 2, Day 3, Day 4, and Day 7
|
|
Gait parameters --- stance phase [%]
Periodo de tiempo: Day 0, Day 2, Day 3, Day 4, and Day 7
|
(1)Measured by plantar pressure distribution measurement systems (100 Hz, FDM-T, Zebris Medical GmbH, Germany) with a maximum gait track of 6 meters. |
Day 0, Day 2, Day 3, Day 4, and Day 7
|
|
Gait parameters --- swing phase [%]
Periodo de tiempo: Day 0, Day 2, Day 3, Day 4, and Day 7
|
(1)Measured by plantar pressure distribution measurement systems (100 Hz, FDM-T, Zebris Medical GmbH, Germany) with a maximum gait track of 6 meters. |
Day 0, Day 2, Day 3, Day 4, and Day 7
|
|
Gait parameters --- double stance phase [%]
Periodo de tiempo: Day 0, Day 2, Day 3, Day 4, and Day 7
|
(1)Measured by plantar pressure distribution measurement systems (100 Hz, FDM-T, Zebris Medical GmbH, Germany) with a maximum gait track of 6 meters. |
Day 0, Day 2, Day 3, Day 4, and Day 7
|
|
Gait parameters --- step time [second]
Periodo de tiempo: Day 0, Day 2, Day 3, Day 4, and Day 7
|
(1)Measured by plantar pressure distribution measurement systems (100 Hz, FDM-T, Zebris Medical GmbH, Germany) with a maximum gait track of 6 meters. |
Day 0, Day 2, Day 3, Day 4, and Day 7
|
|
Gait parameters --- stride time [second]
Periodo de tiempo: Day 0, Day 2, Day 3, Day 4, and Day 7
|
(1)Measured by plantar pressure distribution measurement systems (100 Hz, FDM-T, Zebris Medical GmbH, Germany) with a maximum gait track of 6 meters. |
Day 0, Day 2, Day 3, Day 4, and Day 7
|
|
Gait parameters --- cadence [steps/minute]
Periodo de tiempo: Day 0, Day 2, Day 3, Day 4, and Day 7
|
(1)Measured by plantar pressure distribution measurement systems (100 Hz, FDM-T, Zebris Medical GmbH, Germany) with a maximum gait track of 6 meters. |
Day 0, Day 2, Day 3, Day 4, and Day 7
|
|
Gait parameters --- velocity [km/hour]
Periodo de tiempo: Day 0, Day 2, Day 3, Day 4, and Day 7
|
(1)Measured by plantar pressure distribution measurement systems (100 Hz, FDM-T, Zebris Medical GmbH, Germany) with a maximum gait track of 6 meters. |
Day 0, Day 2, Day 3, Day 4, and Day 7
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Clinical Scale
Periodo de tiempo: Day 0, Day 2, Day 3, Day 4, and Day 7
|
|
Day 0, Day 2, Day 3, Day 4, and Day 7
|
|
Clinical score
Periodo de tiempo: Day 0, Day 2, Day 3, Day 4, and Day 7
|
|
Day 0, Day 2, Day 3, Day 4, and Day 7
|
|
Clinical Scale
Periodo de tiempo: Day 0, Day 2, Day 3, Day 4, and Day 7
|
|
Day 0, Day 2, Day 3, Day 4, and Day 7
|
|
Clinical Scale
Periodo de tiempo: Day 0, Day 2, Day 3, Day 4, and Day 7
|
|
Day 0, Day 2, Day 3, Day 4, and Day 7
|
|
Clinical Scale
Periodo de tiempo: Day 0, Day 2, Day 3, Day 4, and Day 7
|
|
Day 0, Day 2, Day 3, Day 4, and Day 7
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 202307093DINC
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .